Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current Assets    
Cash and cash equivalents $ 76,887 $ 6,227
Prepaid expenses and other current assets 1,749 1,707
Total Current Assets 78,636 7,934
Property and equipment, net 156 174
Right of use asset 239 279
Deposits and other assets 23 23
Total Assets 79,054 8,410
Current Liabilities:    
Accounts payable 621 886
Accrued expenses 854 925
Accrued employee benefits 350 868
Operating lease liability 297 287
Total Current Liabilities 2,122 2,966
Lease liability - long term 108 186
Total Liabilities 2,230 3,152
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 0 12,798
Stockholders' Equity (Deficit):    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 0 2,477
Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at March 31, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020 132 29
Additional paid-in capital 339,019 240,821
Accumulated deficit (259,553) (248,094)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit) 79,598 (4,767)
Non-controlling interest (2,774) (2,773)
Total Stockholders' Equity (Deficit) 76,824 (7,540)
Total Liabilities and Stockholders' Equity (Deficit) $ 79,054 $ 8,410